Diseases [C] » Skin and Connective Tissue Diseases [C17] » Connective Tissue Diseases » Lupus Erythematosus, Systemic
Diseases [C] » Immune System Diseases [C20] » Autoimmune Diseases » Lupus Erythematosus, Systemic
Description
A chronic, relapsing, inflammatory, and often febrile multisystemic disorder of connective tissue, characterized principally by involvement of the skin, joints, kidneys, and serosal membranes. It is of unknown etiology, but is thought to represent a failure of the regulatory mechanisms of the autoimmune system. The disease is marked by a wide range of system dysfunctions, an elevated erythrocyte sedimentation rate, and the formation of LE cells in the blood or bone marrow. MeSH
Hierarchy View
Subtype Terms (2)
Lupus Nephritis
86 drugs (45 approved, 41 experimental)
Lupus Vasculitis, Central Nervous System
1 experimental drug
Approved Indicated Drugs (7)
Phase 4 Indicated Drugs (37)
Phase 3 Indicated Drugs (32)
Organization Involved with Phase 4 Indications (34)
Organization Involved with Phase 3 Indications (50)
Chinese Academy of Medical Sciences
Dutch Working Party on Systemic Lupus Erythematosus
EULAR Lupus Nephritis Trial Network Study Group
Organization Involved with Phase 2 Indications (107)
Ahvaz Jundishapur University of Medical Sciences
Assistance Publique - Hôpitaux de Paris
Beijing InnoCare Pharma Tech Co., Ltd.
Beijing Municipal Science & Technology Commission
Belarusian State Medical University
Ceske Budejovice, Czech Republic
Feinstein Institute for Medical Research
Florida Academic Dermatology Centers
Institut National de la Santé Et de la Recherche Médicale, France
National Academy of Sciences of Belarus
National Cancer Institute (NCI)
National Institute for Health Research, United Kingdom
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
National Institute of Rheumatology, Piestany, Slovakia
National Natural Science Foundation of China
North China Pharmaceutical Group Corporation
Organization Involved with Phase 1 Indications (34)
Organization Involved with Other Experimental Indications (15)
Hierarchy Tree View
UMLS Data
YOU AGREE THAT THE INFORMATION PROVIDED ON THIS WEBSITE IS PROVIDED “AS IS”, WITHOUT ANY WARRANTY OF ANY KIND, EXPRESSED OR IMPLIED, INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE, OR NON-INFRINGEMENT OF ANY THIRD-PARTY PATENT, COPYRIGHT, OR ANY OTHER THIRD-PARTY RIGHT. IN NO EVENT SHALL THE CREATORS OF THE WEBSITE OR WASHINGTON UNIVERSITY BE LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, OR CONSEQUENTIAL DAMAGES ARISING OUT OF OR IN ANY WAY CONNECTED WITH THE WEBSITE, THE USE OF THE WEBSITE, OR THIS AGREEMENT, WHETHER IN BREACH OF CONTRACT, TORT OR OTHERWISE, EVEN IF SUCH PARTY IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
